동물용 의약품 시장 규모, 점유율 및 동향 분석 리포트 : 제품별, 동물별, 투여 경로별, 유통 채널별, 지역별 및 부문 예측(2025-2033년)

Veterinary Medicine Market Summary

The global veterinary medicine market size was estimated at USD 47.70 billion in 2024 and is projected to reach USD 113.48 billion by 2033, growing at a CAGR of 10.36% from 2025 to 2033. The market is propelling due to rising livestock population and increasing pet ownership rates, increasing number of zoonotic & chronic diseases, rising R&D and procedural advancements and increasing consumption of meat and mandatory vaccination.

Global livestock populations and companion-animal ownership are expanding rapidly, driving demand for veterinary medicine. According to the USDFDA report published in October 2025, in the U.S., cattle and calves total accounted for approximately 94.2 million, whereas India's livestock population reached over 535 million in 2019, with significant increases in sheep, goats, and dairy animals. This growth supports herd health management, reproductive monitoring, and preventive care. Similarly, pet ownership is surging worldwide; in the U.S., 71% of households own pets, with an estimated 471 million dogs and 373 million cats globally. Thus, this rising herd and pet numbers increase veterinary visits, preventive treatments, diagnostics, and wellness spending, fueling sustained growth in the veterinary medicine market across companion and production animals.

In addition, rising prevalence of zoonotic and chronic diseases is boosting veterinary pharmaceutical and vaccine demand. Outbreaks of avian influenza, foot-and-mouth disease, and antimicrobial-resistant infections threaten livestock production, human health, and trade, highlighting the need for preventive interventions. Besides this, according to the October 2025 article by Hepper, companion animals are being affected by chronic conditions such as obesity, diabetes, kidney disease, and osteoarthritis, with up to 63% of cats and 30% of dogs overweight or obese. Hence, pet owners' growing concern over health outcomes is driving higher expenditure on treatment, management, and preventive care. Thus, veterinary medicine adoption is accelerating globally, with vaccines, anti-infectives, and therapeutic solutions becoming critical for livestock and companion-animal health.

Furthermore, rising global meat consumption is increasing demand for livestock production and animal health interventions. The annual meat intake exceeds 350 million tons around the globe, with growth driven by Asia, Africa, and Latin America, particularly China. Expanding herds and flocks require effective disease prevention, prompting higher usage of vaccines, anti-infectives, and recombinant biological products. Many countries mandate routine vaccination of cattle and poultry to prevent foodborne illnesses. In addition, rising meat demand, coupled with antibiotic-free production trends, strengthens the need for animal health solutions that maintain herd productivity and biosecurity.

Moreover, innovation in veterinary medicine, including advanced vaccines, biologics, and therapeutics, is driving market growth. Collaborative initiatives such as the Innovative Medicines Initiative (IMI) in Europe and MediLabSecure for emerging pathogens support research and development across multiple countries. Besides this, adoption of veterinary health information systems improves communication and facilitates innovation. Companies continue launching novel products, including MSD Animal Health's NUMELVI for atopic dermatitis in dogs, Virbac's Vikaly medicated cat feed for kidney disease, and ZyVet's FDA-approved generics for urinary incontinence and heart failure. These R&D advances expand treatment options, improve clinical outcomes, and encourage broader adoption of innovative pharmaceuticals and biologics in veterinary practices globally.

Global Veterinary Medicine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the veterinary medicine market report based on product, animal, route of administration, distribution channel and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Biologics
  • Vaccines
  • Modified/ Attenuated Live
  • Inactivated (Killed)
  • Other Vaccines
  • Other Biologics
• Pharmaceuticals
  • Parasiticides
  • Anti-infectives
  • Anti-inflammatory
  • Analgesics
  • Others
• Medicated Feed Additives
• Animal Outlook (Revenue, USD Million, 2021 - 2033)
• Production Animals
  • Poultry
  • Pigs
  • Cattle
  • Sheep & Goats
  • Others
• Companion Animals
  • Dogs
  • Cats
  • Horses
  • Others
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral
• Injectable
• Topical
• Other Routes
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Veterinary Hospitals & Clinics
• E-commerce
• Offline Retail Stores
• Others
• Region Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Animal
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information/Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Model 1: Commodity Flow Analysis
  • 1.7.2. Model 2: Bottom-Up Analysis
  • 1.7.3. Model 3: Volume-Pricing Analysis
• 1.8. List of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary/Related Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rise In Livestock Population and Increasing Pet Ownership Rates
    • 3.2.1.2. Increase In the Number of Zoonotic & Chronic Diseases
    • 3.2.1.3. Rising R&D and Procedural Advancements
    • 3.2.1.4. Increasing Consumption of Meat and Mandatory Vaccination
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Government Intervention
    • 3.2.2.2. Increasing Influx of Counterfeit Drugs
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
  • 3.2.5. Technology Landscape
• 3.3. Pricing Model Analysis
• 3.4. Market Analysis Tools
  • 3.4.1. Porter's Five Forces Analysis
  • 3.4.2. PESTEL by SWOT Analysis

Chapter 4. Veterinary Medicine Market: By Animal Estimates & Trend Analysis

• 4.1. Veterinary Medicine Market, By Animal: Segment Dashboard
• 4.2. Veterinary Medicine Market, By Animal Movement Analysis
• 4.3. Veterinary Medicine Market Estimates & Forecasts, by Animal, 2021 to 2033 (USD Million)
• 4.4. Production Animals
  • 4.4.1. Production Animals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Poultry
    • 4.4.2.1. Poultry Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Pigs
    • 4.4.3.1. Pigs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Cattle
    • 4.4.4.1. Cattle Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.5. Sheep & Goats
    • 4.4.5.1. Sheep & Goats Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Companion animals
  • 4.5.1. Companion Animals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Dogs
    • 4.5.2.1. Dogs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Cats
    • 4.5.3.1. Cats Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Horses
    • 4.5.4.1. Horses Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Veterinary Medicine Market: By Product Estimates & Trend Analysis

• 5.1. Veterinary Medicine Market, By Product: Segment Dashboard
• 5.2. Veterinary Medicine Market, By Product Movement Analysis
• 5.3. Veterinary Medicine Market Estimates & Forecasts, by Product, 2021 to 2033 (USD Million)
• 5.4. Biologics
  • 5.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Vaccines
    • 5.4.2.1. Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.1.1. Modified/ Attenuated Live
        • 5.4.2.1.1.1. Modified/ Attenuated Live Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.1.2. Inactivated (Killed)
        • 5.4.2.1.2.1. Inactivated (Killed) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.1.3. Other Vaccines
        • 5.4.2.1.3.1. Other Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Other Biologics
    • 5.4.3.1. Other Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Pharmaceuticals
  • 5.5.1. Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Parasiticides
    • 5.5.2.1. Parasiticides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Anti-infectives
    • 5.5.3.1. Anti-infectives Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.4. Anti-inflammatory
    • 5.5.4.1. Anti-inflammatory Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.5. Analgesics
    • 5.5.5.1. Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.6. Others
    • 5.5.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Medicated Feed Additives
  • 5.6.1. Medicated Feed Additives Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Veterinary Medicine Market: By Route of Administration Estimates & Trend Analysis

• 6.1. Veterinary Medicine Market, By Route of Administration: Segment Dashboard
• 6.2. Veterinary Medicine Market, By Route of Administration Movement Analysis
• 6.3. Veterinary Medicine Market Estimates & Forecasts, by Route of Administration, 2021 to 2033 (USD Million)
• 6.4. Oral
  • 6.4.1. Oral Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Injectable
  • 6.5.1. Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Topical
  • 6.6.1. Topical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Other Routes
  • 6.7.1. Other Routes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Veterinary Medicine Market: By Distribution Channel Estimates & Trend Analysis

• 7.1. Veterinary Medicine Market, By Distribution Channel: Segment Dashboard
• 7.2. Veterinary Medicine Market, By Distribution Channel Movement Analysis
• 7.3. Veterinary Medicine Market Estimates & Forecasts, by Distribution Channel, 2021 to 2033 (USD Million)
• 7.4. Veterinary Hospitals & Clinics
  • 7.4.1. Veterinary Hospitals & Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. E-commerce
  • 7.5.1. E-commerce Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Offline Retail Stores
  • 7.6.1. Offline Retail Stores Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Veterinary Medicine Market: By Regional Estimates & Trend Analysis

• 8.1. Region Market Dashboard
• 8.2. Region Market Share Analysis, 2024 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. Saudi Arabia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Qatar
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Oman
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Zoetis Inc.
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product/Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Boehringer Ingelheim International Gmbh
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product/Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Merck & Co., Inc.
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product/Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Elanco
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product/Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Dechra Pharmaceuticals PLC
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product/Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Ceva Sante Animale
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product/Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Phibro Animal Health Corporation
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product/Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Virbac
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product/Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Bimeda Corporate
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product/Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Biogenesis Bago
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product/Service Benchmarking
    • 9.3.10.4. Strategic Initiatives